Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex (MAC) Lung Disease: Effect of Baseline Amikacin and Clarithromycin Susceptibility on Culture Conversion

被引：0

作者：

Winthrop, K. L. ^{[1
]}

Flume, P. A. ^{[2
,3
]}

Thomson, R. ^{[4
]}

Brown-Elliott, B. A. ^{[5
]}

Wallace, R. J., Jr. ^{[5
]}

Griffith, D. E. ^{[6
]}

Pennings, L. J. ^{[7
]}

Coulter, C. ^{[8
]}

Syrmis, M. ^{[8
]}

Pandey, S. ^{[8
]}

Yuen, D. ^{[9
]}

Mange, K. ^{[9
]}

van Ingen, J. ^{[7
]}

机构：

[1] Oregon Hlth & Sci Univ, Div Infect Dis, Portland, OR 97201 USA

[2] Med Univ South Carolina, Dept Med, Charleston, SC 29425 USA

[3] Med Univ South Carolina, Dept Pediat, Charleston, SC 29425 USA

[4] Univ Queensland, Gallipoli Med Res Inst, Brisbane, Qld, Australia

[5] Univ Texas Hlth Sci Ctr Tyler, Mycobacteria Nocardia Lab, Tyler, TX USA

[6] Univ Texas Hlth Sci Ctr Tyler, Tyler, TX USA

[7] Radboud Univ Nijmegen Med Ctr, Dept Med Microbiol, Nijmegen, Netherlands

[8] Pathol Queensland, Queensland Mycobacterium Reference Lab, Brisbane, Qld, Australia

[9] Insmed Inc, Bridgewater, NJ USA

来源：

AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2020年 / 201卷

关键词：

D O I：

暂无

中图分类号：

R4 [临床医学];

学科分类号：

1002 ; 100602 ;

摘要：

A4494

引用

页数：2

共 50 条

[1] EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)
Winthrop, Kevin
Eagle, Gina
Morimoto, Kozo
Castellotti, Paola Francesca
O'Donnell, Anne
Ruoss, Stephen
Aksamit, Timothy
Nezamis, James
Griffith, David
CHEST, 2018, 154 (04) : 182A - 183A
[2] RELATIONSHIP BETWEEN IN VITRO CLARITHROMYCIN SUSCEPTIBILITY AND SPUTUM CULTURE CONVERSION WITH ADD-ON AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT OF REFRACTORY MYCOBACTERIUM AVIUM COMPLEX (MAC) LUNG DISEASE
Griffith, David
Eagle, Gina
Wallace, Richard
Brown-Elliott, Barbara
Van Ingen, Jakko
Pennings, Lian
Berry, Brooke
Pandey, Sushil
Coulter, Christopher
Syrmis, Melanie
Morimoto, Kozo
Hasegawa, Naoki
CHEST, 2018, 154 (04) : 109A - 110A
[3] AN OPEN-LABEL EXTENSION STUDY OF AMIKACIN LIPOSOME INHALATION SUSPENSION (ALIS) FOR TREATMENT-REFRACTORY LUNG DISEASE CAUSED BY MYCOBACTERIUM AVIUM COMPLEX (MAC)
Winthrop, Kevin
Morimoto, Kozo
Castellotti, Paola Francesca
Yim, Jae-Joon
Ruoss, Stephen
van Ingen, Jakko
Coulter, Christopher
Mange, Kevin
Nezamis, James
Griffith, David
CHEST, 2019, 156 (04) : 146A - 147A
[4] Amikacin Liposome Inhalation Suspension for Treatment-Refractory Lung Disease Caused by Mycobacterium avium Complex (CONVERT)
Griffith, David E.
Eagle, Gina
Thomson, Rachel
Aksamit, Timothy R.
Hasegawa, Naoki
Morimoto, Kozo
Addrizzo-Harris, Doreen J.
O'Donnell, Anne E.
Marras, Theodore K.
Flume, Patrick A.
Loebinger, Michael R.
Morgan, Lucy
Codecasa, Luigi R.
Hill, Adam T.
Ruoss, Stephen J.
Yim, Jae-Joon
Ringshausen, Felix C.
Field, Stephen K.
Philley, Julie V.
Wallace, Richard J., Jr.
van Ingen, Jakko
Coulter, Chris
Nezamis, James
Winthrop, Kevin L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 198 (12) : 1559 - 1569
[5] Sustainability and Durability of Culture Conversion in Patients Receiving Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Mycobacterium Avium Complex Lung Disease (MAC-LD) in the CONVERT Study
Griffith, D. E.
Thomson, R.
Addrizzo-Harris, D. J.
Field, S. K.
van Ingen, J.
Wallace, R. J., Jr.
Coulter, C.
Mange, K.
Nezamis, J.
Winthrop, K. L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2019, 199
[6] Randomized Phase 3 Trial of Amikacin Liposome Inhalation Suspension (ALIS) for Treatment-Refractory Nontuberculous Mycobacterial (NTM) Lung Disease Caused by Mycobacterium Avium Complex (MAC) in Adult Patients
Griffith, D. E.
Eagle, G.
Thomson, R. M.
Aksamit, T. R.
Hasegawa, N.
Morimoto, K.
Addrizzo-Harris, D. J.
O'Donnell, A. E.
Marras, T. K.
Flume, P. A.
Loebinger, M. R.
Morgan, L. C.
Castellotti, P. F.
Hill, A. T.
Ruoss, S. J.
Yim, J. J.
Ringshausen, F. C.
Field, S. K.
Nezamis, J.
Winthrop, K. L.
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2018, 197
[7] Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection
Zhang, Yang
Hill, Adam T.
EXPERT REVIEW OF RESPIRATORY MEDICINE, 2021, 15 (06) : 737 - 744
[8] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Matt Shirley
Drugs, 2019, 79 : 555 - 562
[9] Amikacin Liposome Inhalation Suspension: A Review in Mycobacterium avium Complex Lung Disease
Shirley, Matt
DRUGS, 2019, 79 (05) : 555 - 562
[10] Amikacin Liposome Inhalation Suspension in Refractory Mycobacterium avium Complex Lung Disease: A Profile of Its Use
Sheridan M. Hoy
Clinical Drug Investigation, 2021, 41 : 405 - 412

← 1 2 3 4 5 →